CEO Lawrence Blatt was paid $4,057,234 in fiscal year 2025, ↑ up 90.0% from fiscal year 2024 (SEC filing 0001193125-26-191843 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$4,057,234 ↑ Lawrence Blatt total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Ask our research desk, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Lawrence Blatt | $651,718 | $0 | $0 | $3,014,995 | $371,479 | $0 | $19,042 | $4,057,234 |
| President and Chief Executive Officer | ||||||||
| Lesley Calhoun | 502,000 | 0 | 0 | 874,929 | 190,760 | 0 | 12,000 | 1,579,689 |
| Executive Vice President, Chief Operating Officer and Chief Financial Officer | ||||||||
| D.Phil. Julian Symons | 492,758 | 0 | 0 | 384,545 | 189,219 | 0 | 12,000 | 1,078,522 |
| Executive Vice President, Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Lawrence Blatt | $4,057,234 | $2,135,283 | — | ↑ +1,921,951 |
| Lesley Calhoun | 1,579,689 | 1,019,746 | — | ↑ +559,943 |
| D.Phil. Julian Symons | 1,078,522 | 834,517 | — | ↑ +244,005 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Aligos Therapeutics, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ALGS reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses ALGS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALGS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Lawrence Blatt | Option | 943 | 35.25 | — |
| Lesley Calhoun | Option | 124 | 24 | — |
| Lawrence Blatt | Option | 23,320 | 11.74 | — |
| Lesley Calhoun | Option | 1,620 | 28.25 | — |
| Lesley Calhoun | Option | 36,000 | 8.68 | — |
| Lesley Calhoun | Option | 291 | 35.25 | — |
| Lawrence Blatt | Option | 21,721 | 28.25 | — |
| Lawrence Blatt | Option | 385 | 24 | — |
| Lesley Calhoun | Option | 306 | 35.25 | — |
| Lawrence Blatt | Option | 161,071 | 8.68 | — |
| Lawrence Blatt | Option | 110,915 | 16.87 | — |
| Lawrence Blatt | Option | 3,031 | 33.5 | — |
| Lesley Calhoun | Option | 760 | 21 | — |
| Lawrence Blatt | Option | 2,375 | 21 | — |
| Lesley Calhoun | Option | 37,423 | 16.87 | — |
| Lesley Calhoun | Option | 7,480 | 11.74 | — |
| Lesley Calhoun | Option | 6,951 | 28.25 | — |
| Lesley Calhoun | Option | 984 | 33.5 | — |
| Lesley Calhoun | Option | 14,334 | 8.68 | — |
| Lesley Calhoun | Option | 17,174 | 16.87 | — |
We seek to ensure that the total compensation paid to our executive officers is reasonable and competitive. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James Scopa, J.D., M.B.AIndependent · Audit (Chair) | $60,000 | — | $35,840 | — | — | $95,840 |
| K. Peter Hirth, Ph.DIndependent · Audit | 53,500 | — | 35,840 | — | — | 89,340 |
| Heather Preston, M.DIndependent · Nominating and Corporate Governance (Chair) | 50,000 | — | 35,840 | — | — | 85,840 |
| Margarita Chavez, J.DIndependent · Audit | 47,500 | — | 35,840 | — | — | 83,340 |
| Bridget Martell, M.A., M.DIndependent · Compensation · Nominating and Corporate Governance | 46,000 | — | 35,840 | — | — | 81,840 |
| Carole Nuechterlein, J.DIndependent · Compensation (Chair) · Nominating and Corporate Governance | 0 | — | 35,840 | — | — | 35,840 |
| Lawrence M. Blatt, Ph.D., M.B.AEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $257,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $257,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Aligos Therapeutics, Inc. | 2025 | Lawrence Blatt | $651,718 | $0 | $3,014,995 | $371,479 | $4,057,234 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Lawrence Blatt | DEF 14A | 2026-04-29 | 0001193125-26-191843 | Section “Executive Compensation”. As printed: 4,057,234. Filing ↗machine: r2 · c23 · span 316707–316716 |
| 2 | Section 01, Lesley Calhoun | DEF 14A | 2026-04-29 | 0001193125-26-191843 | Section “Executive Compensation”. As printed: 1,579,689. Filing ↗machine: r4 · c23 · span 320502–320511 |
| 3 | Section 01, D.Phil. Julian Symons | DEF 14A | 2026-04-29 | 0001193125-26-191843 | Section “Executive Compensation”. As printed: 1,078,522. Filing ↗machine: r6 · c23 · span 324339–324348 |
| 4 | Section 08, James Scopa, J.D., M.B.A | DEF 14A | 2026-04-29 | 0001193125-26-191843 | Section “Director Compensation”. As printed: 95,840. Filing ↗machine: span 293724–293730 |
| 5 | Section 08, K. Peter Hirth, Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191843 | Section “Director Compensation”. As printed: 89,340. Filing ↗machine: span 289345–289351 |
| 6 | Section 08, Heather Preston, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191843 | Section “Director Compensation”. As printed: 85,840. Filing ↗machine: span 292644–292650 |
| 7 | Section 08, Margarita Chavez, J.D | DEF 14A | 2026-04-29 | 0001193125-26-191843 | Section “Director Compensation”. As printed: 83,340. Filing ↗machine: span 288269–288275 |
| 8 | Section 08, Bridget Martell, M.A., M.D | DEF 14A | 2026-04-29 | 0001193125-26-191843 | Section “Director Compensation”. As printed: 81,840. Filing ↗machine: span 290452–290458 |
| 9 | Section 08, Carole Nuechterlein, J.D | DEF 14A | 2026-04-29 | 0001193125-26-191843 | Section “Director Compensation”. As printed: 35,840. Filing ↗machine: span 291279–291285 |
| 10 | Section 08, Lawrence M. Blatt, Ph.D., M.B.A | DEF 14A | 2026-04-29 | 0001193125-26-191843 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 12 | Section 09b board cost (computed) | Computed | — | — | Cash 257,000 + equity 0 + all other 0 = 257,000, summed across the director compensation table rows.machine: formula: Σ = 257,000 |
| 13 | Aligos Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191843 | CEO total compensation as printed in Aligos Therapeutics, Inc.'s own proxy. As printed: 4,057,234. Filing ↗machine: r2 · c23 · span 316707–316716 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat